PL370459A1 - Retynoidowi agoniści II typu podstawionego mocznika - Google Patents
Retynoidowi agoniści II typu podstawionego mocznikaInfo
- Publication number
- PL370459A1 PL370459A1 PL02370459A PL37045902A PL370459A1 PL 370459 A1 PL370459 A1 PL 370459A1 PL 02370459 A PL02370459 A PL 02370459A PL 37045902 A PL37045902 A PL 37045902A PL 370459 A1 PL370459 A1 PL 370459A1
- Authority
- PL
- Poland
- Prior art keywords
- substituted urea
- cancer
- emphysema
- retinoid agonists
- dermatological disorders
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- 239000004202 carbamide Substances 0.000 title 1
- -1 urea retinoid Chemical class 0.000 title 1
- 206010014561 Emphysema Diseases 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32296201P | 2001-09-18 | 2001-09-18 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL370459A1 true PL370459A1 (pl) | 2005-05-30 |
| PL209697B1 PL209697B1 (pl) | 2011-10-31 |
Family
ID=23257206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL370459A PL209697B1 (pl) | 2001-09-18 | 2002-09-11 | Pochodne mocznika, środek farmaceutyczny i zastosowanie pochodnych mocznika |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6838472B2 (pl) |
| EP (1) | EP1430023B1 (pl) |
| JP (1) | JP4410562B2 (pl) |
| KR (1) | KR100891224B1 (pl) |
| CN (1) | CN1301968C (pl) |
| AR (1) | AR036532A1 (pl) |
| AT (1) | ATE427929T1 (pl) |
| AU (1) | AU2002340886B2 (pl) |
| BR (1) | BR0212607A (pl) |
| CA (1) | CA2458266C (pl) |
| DE (1) | DE60231888D1 (pl) |
| ES (1) | ES2325063T3 (pl) |
| MX (1) | MXPA04002305A (pl) |
| PL (1) | PL209697B1 (pl) |
| RU (1) | RU2303027C2 (pl) |
| WO (1) | WO2003024920A1 (pl) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1889837A1 (en) * | 2006-07-10 | 2008-02-20 | Pharmeste S.r.l. | VR1 vanilloid receptor antagonists with a iononic substructure |
| EP1889830A1 (en) | 2006-07-10 | 2008-02-20 | Pharmeste S.r.l. | Biarylcarboxyarylamides as vanilloid-1 receptor modulators |
| HUE051664T2 (hu) | 2010-09-01 | 2021-03-29 | Univ Jefferson | Összetétel és módszer az izomjavításra és a regenerációra |
| SG10201704687YA (en) | 2012-11-08 | 2017-07-28 | Univ Yamaguchi | Therapeutic agent for keratoconjunctive disorders |
| BR112015029114B1 (pt) | 2013-05-22 | 2020-11-24 | Yamaguchi University | composição |
| WO2017210792A1 (en) | 2016-06-08 | 2017-12-14 | Clementia Pharmaceuticals Inc. | Methods for treating heterotopic ossification |
| US10980778B2 (en) | 2016-11-16 | 2021-04-20 | Clementia Pharmaceuticals Inc. | Methods for treating multiple osteochondroma (MO) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU87821A1 (fr) | 1990-10-12 | 1992-05-25 | Cird Galderma | Composes bi-aromatiques,et leur utilisation en medecine humaine et veterinaire et en cosmetique |
| HUT62558A (en) * | 1991-07-01 | 1993-05-28 | Sandoz Ag | Process for producing n-phenylthiourea derivaties and pharmaceutical compositions comprising same |
| US5648514A (en) * | 1994-12-29 | 1997-07-15 | Allergan | Substituted acetylenes having retinoid-like biological activity |
| US5599967A (en) * | 1994-12-29 | 1997-02-04 | Allergan | Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl of heteroaryl group having retinoid-like biological activity |
| US6093742A (en) * | 1997-06-27 | 2000-07-25 | Vertex Pharmaceuticals, Inc. | Inhibitors of p38 |
| JO2178B1 (en) * | 1999-10-19 | 2003-04-23 | اف . هوفمان لاروش ايه جي | Treatment of invasive diseases, using selected anti-PAR materials |
-
2002
- 2002-09-11 MX MXPA04002305A patent/MXPA04002305A/es active IP Right Grant
- 2002-09-11 AU AU2002340886A patent/AU2002340886B2/en not_active Ceased
- 2002-09-11 WO PCT/EP2002/010181 patent/WO2003024920A1/en not_active Ceased
- 2002-09-11 RU RU2004111789/04A patent/RU2303027C2/ru not_active IP Right Cessation
- 2002-09-11 BR BR0212607-9A patent/BR0212607A/pt not_active IP Right Cessation
- 2002-09-11 KR KR1020047003921A patent/KR100891224B1/ko not_active Expired - Fee Related
- 2002-09-11 DE DE60231888T patent/DE60231888D1/de not_active Expired - Lifetime
- 2002-09-11 EP EP02774599A patent/EP1430023B1/en not_active Expired - Lifetime
- 2002-09-11 JP JP2003528768A patent/JP4410562B2/ja not_active Expired - Fee Related
- 2002-09-11 ES ES02774599T patent/ES2325063T3/es not_active Expired - Lifetime
- 2002-09-11 AT AT02774599T patent/ATE427929T1/de active
- 2002-09-11 CN CNB028178327A patent/CN1301968C/zh not_active Expired - Fee Related
- 2002-09-11 CA CA2458266A patent/CA2458266C/en not_active Expired - Fee Related
- 2002-09-11 PL PL370459A patent/PL209697B1/pl not_active IP Right Cessation
- 2002-09-16 AR ARP020103489A patent/AR036532A1/es not_active Application Discontinuation
- 2002-09-17 US US10/244,885 patent/US6838472B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| RU2004111789A (ru) | 2005-10-20 |
| MXPA04002305A (es) | 2004-06-29 |
| PL209697B1 (pl) | 2011-10-31 |
| BR0212607A (pt) | 2004-08-17 |
| JP2005503411A (ja) | 2005-02-03 |
| RU2303027C2 (ru) | 2007-07-20 |
| WO2003024920A1 (en) | 2003-03-27 |
| KR20040035808A (ko) | 2004-04-29 |
| EP1430023B1 (en) | 2009-04-08 |
| CN1301968C (zh) | 2007-02-28 |
| AU2002340886B2 (en) | 2008-01-31 |
| CA2458266A1 (en) | 2003-03-27 |
| CA2458266C (en) | 2011-03-15 |
| CN1555357A (zh) | 2004-12-15 |
| JP4410562B2 (ja) | 2010-02-03 |
| AR036532A1 (es) | 2004-09-15 |
| US6838472B2 (en) | 2005-01-04 |
| DE60231888D1 (de) | 2009-05-20 |
| ATE427929T1 (de) | 2009-04-15 |
| US20030125383A1 (en) | 2003-07-03 |
| KR100891224B1 (ko) | 2009-04-01 |
| ES2325063T3 (es) | 2009-08-25 |
| EP1430023A1 (en) | 2004-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JO2434B1 (en) | New retinoids to treat emphysema | |
| CA2449729A1 (en) | Prodrugs of gaba analogs, compositions and uses thereof | |
| AU2003256755A1 (en) | Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations | |
| MXPA04002070A (es) | Compuestos de indazol sustituidos para el tratamiento de la inflamacion. | |
| PL369108A1 (pl) | Inhibitory dehydrogenazy 17 beta-hydroksysteroidowej typu 3 do leczenia chorób zależnych od androgenu | |
| IL162214A0 (en) | Pyridine derivatives and pharmaceutical compositions containing the same | |
| AU2002321105A1 (en) | Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis | |
| WO2004043341A3 (en) | Treatment for hemorrhagic shock | |
| EP0923376A4 (en) | TREATMENT OF ASTHMA AND RESPIRATORY DISEASES | |
| IL138476A0 (en) | Method for treating pharmaceutical compositions by special use of anti-oxidant | |
| WO2005046603A3 (en) | Pyridine compounds | |
| MXPA03010761A (es) | Combinaciones farmaceuticas. | |
| MY141528A (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
| PL370361A1 (pl) | Retynoidowi agoniści I typu alkilomocznika | |
| TW200505443A (en) | Combination of SCR kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases | |
| AU4179399A (en) | Use of nmda antagonists and/or sodium channel antagonists for the treatment of inflammatory disorders | |
| WO2004073615A3 (en) | Deazaflavin compounds and methods of use thereof | |
| PL370459A1 (pl) | Retynoidowi agoniści II typu podstawionego mocznika | |
| GB9907571D0 (en) | Compounds | |
| DE69917005D1 (de) | Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung | |
| WO2002041831A3 (en) | Inositol derivatives for increasing chloride secretion and inhibiting inflammation | |
| AU3919001A (en) | Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers | |
| IL168308A (en) | Compositions containing roflumilast and formoterol | |
| WO2002096870A3 (en) | Sponge-derived terpenoids and methods of use | |
| UA66932C2 (en) | Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Decisions on the lapse of the protection rights |
Effective date: 20120911 |